Citations
32 citation(s) found for "Podoltsev, Nikolai".
Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort
Stahl, Maximilian , DeVeaux, Michelle, Montesinos, Pau , Itzykson, Raphaël , Ritchie, Ellen K. , Sekeres, Mikkael A. , Brunner, Andrew M. , Komrokji, Rami S. , Bhatt, Vijaya Raj , Al‐Kali, Aref , Cluzeau, Thomas , Santini, Valeria , Fathi, Amir T. , Fenaux, Pierre , Litzow, Mark R. , Kim, Tae Kon , Vey, Norbert , Germing, Ulrich, Bergua, Juan , Gore, Steven D. , Zeidan, Amer M. , Komrokji, Rami S , Bergua, Juan Miguel , Sekeres, Mikkael A , Montesinos, Pau , Bhatt, Vijaya Raj , Itzykson, Raphael , Santini, Valeria , Kim, Tae Kon , Barnard, John , Podoltsev, Nikolai , Roboz, Gail J. , Perreault, Sarah , Prébet, Thomas , Verma, Vivek , Germing, Ulrich , Serrano, Josefina , Zeidan, Amer M
Blood Advances | April 23, 2018 | Volume: 2 | Issue: 8 | Pages: 923-932
10.1182/bloodadvances.2018016121
| PMID 29685952
Key Points In the largest study of HMAs in RR-AML to date, 16% of patients achieved CR/CRi and experienced a median OS of 21 months. Low proliferative disease (peripheral blood blasts <5%) was associated with improved response and OS.
Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States
Pine, Alexander B. , Sekeres, Mikkael A. , Zelterman, Daniel , Komrokji, Rami S. , Litzow, Mark R. , Luger, Selina M. , Stone, Richard M. , Garcia‐Manero, Guillermo , Lee, Alfred Ian , Barbarotta, Lisa, Kasberg, Stephanie, Gore, Steven D. , Zeidan, Amer M. , Lee, Eun‐Ju , Steensma, David P. , Prébet, Thomas , Dezern, Amy Elizabeth , Erba, Harry Paul , Podoltsev, Nikolai , Hendrickson, Jeanne E. , Komrokji, Rami S , Sekeres, Mikkael A , Zeidan, Amer M
Transfusion | November 23, 2016 | Volume: 57 | Issue: 2 | Pages: 289-295
10.1111/trf.13934
| PMID 27878822
BACKGROUNDTransfusion of blood products is a key component of the supportive management in patients with acute leukemia (AL). However high‐quality trial evidence and clinical outcome data to support specific transfusion goals for blood products for patients with AL remain limited leading to diverse transfusion practices. The primary objective of this study was to determine the spectrum of transfusion patterns in a variety of care settings among providers who treat AL patients.STUDY DESIGN AND METHODSA 31‐question survey queried providers caring for AL patients about the existence of institutional guidelines for transfusion of blood products, transfusion triggers for hemoglobin (Hb), platelets (PLTs), and fibrinogen in various settings including inpatient and outpatient and before procedures.RESULTSWe analyzed 130 responses and identified divergent transfusion Hb goals in hospitalized and ambulatory patients, fibrinogen goals for cryoprecipitate transfusions, and variation in practice for use of certain PLTs and red blood cell products. The least variable transfusion patterns were reported for PLT goals in thrombocytopenia and in the setting of invasive procedures such as bone marrow biopsy and lumbar punctures.CONCLUSIONSThis survey confirmed wide variations in blood product transfusion practices across several clinical scenarios in patients with AL. The findings emphasized the need for large prospective randomized trials to develop standardized evidence‐based guidelines for blood product transfusions in patients with AL with the goal of limiting unnecessary transfusions without compromising outcomes.